PURPOSE: To explore the attitudes, opinions and concerns of minority women regarding acceptance of a potential HIV/ AIDS vaccine. METHODS: In-depth interviews were conducted with high-risk minority women (> or =18 years of age) attending an urban Atlanta health clinic specializing in sexually transmitted diseases, including HIV/AIDS prevention and treatment. Interviews were transcribed and content analyzed to identify common factors related to acceptance of an HIV/AIDS vaccine. RESULTS: Nine major themes were identified. These were general acceptance of an HIV/AIDS vaccine, concerns about the vaccine, vaccine knowledge, testing and research, provider recommendation, mistrust, alternative medicine, misperceptions and vaccine accessibility/availability. A strong theme emerged about the need for information from HIV/AIDS vaccine clinical trials, including the demographics of the studies' volunteer base, to inform decision-making about taking an HIV/AIDS vaccine in the future. CONCLUSIONS: Although fewer than half of the women indicated they would receive or recommend the vaccine, most agreed that development of a vaccine was an important endeavor. The findings of this study may assist in future efforts to determine how best to promote acceptance of an HIV/AIDS vaccine to minority women should one become available.
PURPOSE: To explore the attitudes, opinions and concerns of minority women regarding acceptance of a potential HIV/ AIDS vaccine. METHODS: In-depth interviews were conducted with high-risk minority women (> or =18 years of age) attending an urban Atlanta health clinic specializing in sexually transmitted diseases, including HIV/AIDS prevention and treatment. Interviews were transcribed and content analyzed to identify common factors related to acceptance of an HIV/AIDS vaccine. RESULTS: Nine major themes were identified. These were general acceptance of an HIV/AIDS vaccine, concerns about the vaccine, vaccine knowledge, testing and research, provider recommendation, mistrust, alternative medicine, misperceptions and vaccine accessibility/availability. A strong theme emerged about the need for information from HIV/AIDS vaccine clinical trials, including the demographics of the studies' volunteer base, to inform decision-making about taking an HIV/AIDS vaccine in the future. CONCLUSIONS: Although fewer than half of the women indicated they would receive or recommend the vaccine, most agreed that development of a vaccine was an important endeavor. The findings of this study may assist in future efforts to determine how best to promote acceptance of an HIV/AIDS vaccine to minority women should one become available.
Authors: Malika Roman Isler; Andre L Brown; Natalie Eley; Allison Mathews; Kendra Batten; Randy Rogers; Noah Powell; Caressa White; Rosalee Underwood; Kathleen M MacQueen Journal: Prog Community Health Partnersh Date: 2014
Authors: Stanley D Rosenberg; Richard W Goldberg; Lisa B Dixon; George L Wolford; Eric P Slade; Seth Himelhoch; Gerard Gallucci; Wendy Potts; Stephanie Tapscott; Christopher J Welsh Journal: Psychiatr Serv Date: 2010-09 Impact factor: 3.084
Authors: Paula M Frew; Matthew Archibald; Dazon Dixon Diallo; Su-I Hou; Takeia Horton; Kayshin Chan; Mark J Mulligan; Carlos del Rio Journal: Prev Sci Date: 2010-06
Authors: Julia Painter; Clare Cene-Kush; Alaina Conner; Carrie Cwiak; Lisa Haddad; Mark Mulligan; Ralph DiClemente Journal: Vaccines (Basel) Date: 2013-04-08